What happened

Axon Enterprise — the TASER and police body-camera company — is down about 9.3% today, near $444.77 against yesterday's $490.18 close, as reported by Yahoo Finance. It's among the S&P 500's worst performers on the day.

Nothing broke at the company. Before the open, Axon launched a $1.0 billion offering of 0% convertible senior notes due September 2031, plus a $150 million over-allotment option, per the 8-K and prospectus supplement it filed with the SEC.

So it's borrowing a billion dollars at zero interest — and the stock fell nearly a tenth.

Why it moved

A convertible bond is a loan that can turn into shares. The lender gives up interest because they get an option instead: if the stock climbs past a set conversion price, they convert and take stock. Axon's notes pay no regular interest and the principal doesn't accrete. The option is the payment.

Here's what the headline hides, and Axon says it plainly in its own prospectus: most buyers aren't betting the stock goes up. They're convertible-arbitrage funds. The filing states investors "would typically implement such a strategy by selling short the common stock underlying the notes and dynamically adjusting their short position while continuing to hold the notes." They want the volatility, not the direction — so they buy the bond and short the equity against it, on day one, in size.

That's mechanical supply hitting the tape, not a judgement on the business. Two checks it's Axon's own story and not a sector wobble: Motorola Solutions, its closest listed peer, moved just −0.26%, and the 10-year Treasury yield rose only about 3 basis points to 4.99%. High yields do squeeze expensive stocks — but they didn't take 9% out of Axon this morning.

What 0% signals

In March 2025 Axon raised debt at 6.125% and 6.250% coupons, as reported by Financial News. Today it pays nothing. In the same 8-K it amended its JPMorgan credit agreement to lift the revolver from $300m to $500m (another $150m available) at SOFR plus 1.25%–1.75%. It also bought capped call contracts, a hedge that raises the share price at which real dilution starts. Banks don't hand a company free money, a bigger revolver and a dilution cushion if they're nervous about it.

The business

Axon isn't one product. It reports two segments, and Q2 2026 split almost evenly: Connected Devices $507m (TASERs, body and in-car cameras, drones, counter-drone, VR training) and Software & Services $398m (Axon Evidence, Draft One, Records, Fusus). Revenue was $904m, up 35%, recurring revenue $1.6bn, up 39%, net revenue retention 126%. Full-year guidance was raised to 32–34% growth.

Valuation

On stockanalysis.com's reported figures, Axon's market cap is $35.55bn at a trailing P/E of 182, forward P/E 48.7, price/book 10.8. Motorola Solutions — $78.47bn, growing revenue 10.3% — trades at a trailing P/E of 37.3 and forward 26.2. Axon's own year-end history, per Macrotrends: 81.7 (2022), 110.9 (2023), 123.8 (2024), peaking near 376 at end-2025. The gap between 182 trailing and 48.7 forward is largely stock compensation, guided at $590–620m this year — which is why Q2 GAAP net income was $29m against $155m non-GAAP.

Who it touches

• Axon holders — hedging pressure usually fades once the deal prices and the arb books are set. The dilution, capped or not, doesn't.
• Other high-multiple US tech — a 0% five-year convert clearing the market reopens a financing window others will test; watch the movers list for copycats.
• Motorola Solutions and public-safety rivals — Axon just added roughly $1bn of acquisition firepower in a market they compete in.

What to watch

The conversion price and the capped-call cap price get set when the deal prices. They decide how far the stock must rise before shareholders are actually diluted, and neither was in today's preliminary filing. Per the prospectus, the quarterly conversion trigger only begins for quarters commencing after 31 December 2026 — worth marking on the calendar.

The risk that flips this: if Axon spends the $1bn on an acquisition that dilutes growth instead of adding to it, a forward multiple near 49x leaves very little room to absorb the mistake.

As of 11:50 am ET, 15 September 2026. Sources: Axon Form 8-K (SEC), Axon prospectus supplement (SEC), Axon Q2 2026 results, Financial News, Yahoo Finance, stockanalysis.com, Macrotrends. For discussion and education only — not investment advice. Verify before acting.